Similarly, proteomic and biological profiling discovered that in AD patients, brain-derived MGEVs contain elevated levels of signature proteins such as β-amyloid and tau, along with glial-specific molecules like ANXA5, VGF, GPM6A, and ACTZ. The gene discussed is MAPT; the disease is Alzheimer disease.